Sugentech Inc (253840.KQ) stock: key figures, P/E, revenue and dividend
Energy · Coal & Consumable Fuels · South Korea · ISIN KR7253840003
Sugentech Inc financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 10.10 bn KRW | 9.42 bn KRW |
| Gross profit | -1.21 bn KRW | 811.11 m KRW |
| Operating income | -25.39 bn KRW | -18.82 bn KRW |
| EBIT | -20.28 bn KRW | -22.78 bn KRW |
| Net income | -15.19 bn KRW | -23.31 bn KRW |
| Diluted EPS – continuing operations | -993.66 KRW | -1,524.85 KRW |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Sugentech Inc
Sugentech Inc. develops and sells in-vitro diagnostic systems and products based on biotechnology, information technology, and nanotechnology in South Korea and internationally. The company offers lab tests, including systems and test items; and COVID-19 tests. It also provides point of care testing analyzers and test items for testing of influenza A/B, antibody test, COVID-19 and flu, SARS-CoV-2, HbA1c, beta-hcg, YSH, T3/T4, and CRP; and digital health and home tests, including mobile health, ovulation, and pregnancy products. The company was formerly known as Accugen Healthcare, Inc. and changed its name to Sugentech Inc. in October 2013. Sugentech Inc. was founded in 2011 and is headquartered in Daejeon, South Korea.
More stocks
- Laredo Oil, Inc. (LRDC)
- Grove Collaborative Holdings, Inc. (GROV)
- NEUROPHET, Inc. (380550.KQ)
- Cj Seafood (011150.KS)
- SAGA COMMUNICATIONS INC (SGA)
- Osang Healthcare Co.,Ltd (036220.KQ)
- IMPACT BIOMEDICAL INC. (IBO)
- READING INTERNATIONAL INC (RDI)
- Sinsin Pharmaceutical Co. Ltd (002800.KQ)
- Semi Total Solution Inc. (0017J0.KQ)
- Noble Development Public Company Limited (NOBLE.BK)
- Renalytix plc (RENXF)
Not investment advice. All data without warranty, price as of 16.11.2026. Details in the risk notice.